SY-5609 is under clinical development by Syros Pharmaceuticals and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase I drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SY-5609 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SY-5609 overview
SY-5609 is under development for the treatment of small cell lung cancer, colorectal cancer, HR positive, HER2 negative metastatic breast cancer, ovarian cancer, metastatic pancreatic cancer, pancreatic ductal adenocarcinoma and other solid tumors. It is administered orally. The drug candidate acts by targeting Cyclin Dependent Kinase 7 (CDK7).
It was also under development for the treatment of mantle cell lymphoma and triple-negative breast cancer.
Syros Pharmaceuticals overview
Syros Pharmaceuticals (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company offers its pipeline products under clinical trials including Tamibarotene, an oral potent and selective RARa agonist targets acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); SY-2101, a arsenic trioxide (ATO) for the treatment of acute promyelocytic Leukemia; SY-5609, a highly selective and potent oral inhibitor treats pancreatic cancer and BRAFT-mutant colorectal cancer. It offers services such as gene regulation, research and drug development, drug discovery, clinical trials among others. Syros is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of SY-5609’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
